StockNews.com began coverage on shares of Oragenics (NYSE:OGEN – Free Report) in a research report released on Wednesday morning. The brokerage issued a sell rating on the stock.
Oragenics Trading Down 19.3 %
NYSE OGEN opened at $1.80 on Wednesday. The business’s 50-day moving average is $1.25. The firm has a market cap of $8.07 million, a PE ratio of -0.21 and a beta of 0.50. Oragenics has a 52-week low of $0.86 and a 52-week high of $7.74.
Oragenics (NYSE:OGEN – Get Free Report) last released its quarterly earnings results on Friday, August 9th. The company reported ($0.51) earnings per share (EPS) for the quarter.
Institutional Investors Weigh In On Oragenics
About Oragenics
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Recommended Stories
- Five stocks we like better than Oragenics
- What Are Growth Stocks and Investing in Them
- 3 High-Potential Stocks Analysts Say Could Soar
- About the Markup Calculator
- Brinker International’s Price Dip is an Appetizing Entry Point
- 3 Small Caps With Big Return Potential
- 3 Stocks That Could Beat the September Blues
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.